<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352114</url>
  </required_header>
  <id_info>
    <org_study_id>17517</org_study_id>
    <secondary_id>J2L-MC-EZBA</secondary_id>
    <nct_id>NCT04352114</nct_id>
  </id_info>
  <brief_title>A Study of LY3461767 in Healthy Participants</brief_title>
  <official_title>A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3461767 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study in healthy participants is to learn more about the safety of
      LY3461767 and any side effects that might be associated with it. The study will also measure
      how much LY3461767 gets into the bloodstream and how long it takes the body to get rid of it.
      For each participant, the study will last about 11 weeks, including screening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3461767</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>PK: Cmax of LY3461767</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3461767</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>PK: AUC of LY3461767</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3461767 - Subcutaneous (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3461767 administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3461767 - Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3461767 administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3461767 - SC</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3461767 - Subcutaneous (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3461767 - IV</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3461767 - Intravenous (IV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SC</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo - SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are healthy males, or females of non-child-bearing potential

          -  Have a body mass index of 18 to 35 kilograms per square meter (kg/mÂ²)

          -  Have clinical laboratory tests within normal ranges as judged by investigator

          -  Have pulse rate and blood pressure within normal ranges as judged by investigator

        Exclusion Criteria:

          -  Have Troponin I results above the upper reference limit, and judged to be clinically
             significant by the investigator, at screening

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) at screening

          -  Have a significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal (GI), endocrine, hematological, or neurological disorders

          -  Regularly use known drugs of abuse

          -  Have donated blood of more than 450 milliliters (mL), or have participated in a
             clinical study that required similar blood volume collected within the past 3 months

          -  Have an average weekly alcohol intake that exceeds 7 units per week or are unwilling
             to stop alcohol consumption as required during the study

          -  Smoke more than 10 cigarettes per day

          -  Are current or former smokers with 30-pack-year smoking history

          -  Have a diagnosis or history of any malignancy

          -  Have not had appropriate cancer screening, in accordance with country specific
             guidance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>386-366-6446</phone>
    </contact>
    <investigator>
      <last_name>Hugh A Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>214-647-9305</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lilly Nus Centre for Clin Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>65 67736702</phone>
    </contact>
    <investigator>
      <last_name>Ronan Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1, 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

